This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
BSX Set to Report Q3 Earnings: Will MedSurg Strength Aid Performance?
by Zacks Equity Research
Boston Scientific's Q3 results hinge on MedSurg strength in Endoscopy and Neuromodulation, as Cardiovascular faces competitive pressures and softer sales.
BSXNegative Net Change BDXNegative Net Change IDXXNegative Net Change PAHCPositive Net Change
earnings medical medical-devices
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical???s biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
WSTNegative Net Change EWNegative Net Change GMEDNegative Net Change GKOSNegative Net Change
medical medical-devices
Intuitive Surgical's Q3 Earnings Beat Estimates on Strong System Sales
by Zacks Equity Research
ISRG's Q3 2026 earnings beat estimates as strong system placements, rising procedure volumes and improving margins fuel double-digit revenue growth.
ISRGNegative Net Change EWNegative Net Change GMEDNegative Net Change GKOSNegative Net Change
earnings medical medical-devices
ABT Stock Down Post Q3 Earnings Miss, Revenues Rise Y/Y, Margins Up
by Zacks Equity Research
Abbott's Q3 earnings miss weighs on its stock despite double-digit revenue growth and expanding margins, while lower 2026 sales guidance raises concerns.
ABTPositive Net Change ANegative Net Change GMEDNegative Net Change PAHCPositive Net Change
earnings medical medical-devices
Stryker's Sonopet 3 Secures FDA Clearance to Improve Surgical Accuracy
by Zacks Equity Research
SYK's Sonopet 3 secures FDA clearance, promising enhanced surgical precision and efficiency, with a full commercial launch expected later this fall.
SYKNegative Net Change MMSINegative Net Change OPKNo Net Change GMEDNegative Net Change
medical medical-devices
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
by Zacks Equity Research
DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.
DXCMPositive Net Change ABTPositive Net Change MDTNegative Net Change PODDNegative Net Change
medical medical-devices
Zacks Initiates Coverage of Nortech With Neutral Recommendation
by Zacks Equity Research
Discover why Zacks rates Nortech as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore NSYS' improving profitability and stronger medical-market demand amid persistent cash outflows and customer concentration risks.
NSYSNegative Net Change
electronics medical medical-devices tech-stocks
Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows
by Zacks Equity Research
WAT's AI Link launch and Anthropic collaboration aim to automate LC-MS workflows, streamline lab operations and drive instrument demand.
WATNegative Net Change DHRNegative Net Change ANegative Net Change TMONegative Net Change
medical medical-devices
GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe
by Zacks Equity Research
GE HealthCare secures CE Mark certification for MINItrace Magni and expands Copper-64 production capabilities, strengthening its PET imaging and theranostics portfolio.
GEHCPositive Net Change LNTHPositive Net Change TLXNegative Net Change RADXNegative Net Change
medical medical-devices
How CVS' Aetna Is Advancing Efforts to Reduce Administrative Burden
by Moumi Mondal
CVS Health's Aetna streamlines prior authorizations, approves more than 95% of eligible requests within 24 hours and expands bundled approvals to speed access to care.
CVSNegative Net Change HUMNegative Net Change CINegative Net Change
medical medical-devices